Comparar compuestos

Start

0.1 mg each

Range

0.1–0.3 mg each

Frequency

Once daily, before bed, 5 days on / 2 off

Cycle

8–12 weeks

Vials

10 mg

This pairs a GHRH analog (acts on the pituitary GHRH receptor) with ipamorelin, a selective ghrelin-receptor (GHS-R1a) agonist. The two pathways both trigger growth-hormone release. Ipamorelin was described as the first GH secretagogue that did not raise ACTH or cortisol much in animal studies.

• CJC-1295 (the DAC version) in healthy adults: one injection raised mean GH 2–10-fold for 6 days or more and IGF-1 1.5–3-fold for 9–11 days.
• Ipamorelin released GH in rats and pigs with little change in ACTH or cortisol, unlike earlier GHRPs.
• The cited human CJC-1295 study used albumin-binding DAC material; it does not establish the pharmacokinetics of the no-DAC component or this premixed blend.

• Neither component is FDA-approved; both are on the World Anti-Doping Agency prohibited list.
• No serious adverse reactions were reported in the CJC-1295 trials in healthy adults.
• No controlled trial of this specific premixed no-DAC blend was identified in the targeted source review; the cited studies concern individual components, not mixture safety or efficacy.

2 referencias · ver